Search

Displaying results 421 - 430 of 2507 in total
  1. Drug

    Vinflunine

    go.drugbank.com/drugs/DB11641
    ApprovedInvestigational

    Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    PF-08046052

    go.drugbank.com/drugs/DB22647
    Investigational

    PF-08046052 is under investigation in clinical trial NCT05983133 (A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors).

  3. Drug

    PF-04620110

    go.drugbank.com/drugs/DB14887
    Investigational

    PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).

  4. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted f...

  5. Drug

    PF-05089771

    go.drugbank.com/drugs/DB14856
    Investigational

    PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).

  6. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (...

  7. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  8. Drug

    Doconexent

    go.drugbank.com/drugs/DB03756
    ApprovedInvestigational

    A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic aci...

    Mixtures: P-NATAL®, Virt-Pn DHACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors
  9. Drug

    PF-06882961

    go.drugbank.com/drugs/DB16043
    Investigational

    PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

  10. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes